Adage Capital Partners’s Bright Minds Biosciences DRUG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$16.2M Sell
324,800
-10,200
-3% -$720K 0.02% 593
2026
Q2
$23.5M Sell
335,000
-160,743
-32% -$12.6M 0.03% 451
2026
Q1
$36.2M Buy
495,743
+100,000
+25% +$8.05M 0.06% 320
2025
Q4
$30.9M Hold
395,743
– – 0.05% 359
2025
Q3
$24M Buy
395,743
+195,743
+98% +$7.6M 0.04% 415
2025
Q2
$5.22M Hold
200,000
– – 0.01% 701
2025
Q1
$7.21M Buy
200,000
+67,500
+51% +$2.47M 0.01% 644
2024
Q4
$4.77M Buy
+132,500
New +$4.66M 0.01% 722

Other funds holding DRUG

Adage Capital Partners's DRUG Position: Q3 2026 in Review

Adage Capital Partners reduced its Bright Minds Biosciences (DRUG) stake by 3% in Q3 2026, selling an estimated $720K and leaving 324,800 shares worth $16.2M. The position accounts for 0.02% of the portfolio, ranked #593.

Adage Capital Partners first reported a position in DRUG in Q4 2024 and has held it in 8 quarters since. The position peaked at $36.2M in Q1 2026. 109 funds tracked by Wall St. Rank hold DRUG as of Q3 2026.

  • Adage Capital Partners held 324,800 shares of Bright Minds Biosciences worth $16.2M as of Q3 2026.
  • Adage Capital Partners sold 10,200 Bright Minds Biosciences shares in Q3 2026, an estimated $720K.
  • Bright Minds Biosciences made up 0.02% of Adage Capital Partners's portfolio in Q3 2026, its #593 holding.
  • Adage Capital Partners first reported a position in Bright Minds Biosciences in Q4 2024 and has held it in 8 quarters since.
  • Adage Capital Partners's Bright Minds Biosciences position peaked at $36.2M in Q1 2026.
  • 109 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q3 2026.

Based on Adage Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.